scholarly article | Q13442814 |
P50 | author | Eric D. Peterson | Q63021326 |
P2093 | author name string | Lesley H Curtis | |
Adrian F Hernandez | |||
Robert J Mentz | |||
Emily C O'Brien | |||
Lisa G Berdan | |||
Jenny C Ibarra | |||
Tyrus Rorick | |||
P2860 | cites work | Evidence based medicine: what it is and what it isn't | Q24655756 |
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 | ||
Care patterns in Medicare and their implications for pay for performance | Q28293001 | ||
Challenges in using electronic health record data for CER: experience of 4 learning organizations and solutions applied | Q30649679 | ||
Mini-Sentinel and regulatory science--big data rendered fit and functional | Q30828989 | ||
Independent data monitoring committees: preparing a path for the future | Q30838979 | ||
The unintended consequences of clinical trials regulations | Q30887196 | ||
Secondary Use of EHR: Data Quality Issues and Informatics Opportunities. | Q33828209 | ||
Allocation concealment in randomised trials: defending against deciphering | Q34116070 | ||
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials | Q34157981 | ||
Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). | Q34218558 | ||
Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy | Q34264600 | ||
Quantifying the magnitude and cost of collecting extraneous protocol data | Q34594386 | ||
A brief review of the Belmont report | Q34620516 | ||
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers | Q34974411 | ||
Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study | Q34995068 | ||
External validity of randomised controlled trials: "to whom do the results of this trial apply?". | Q36003704 | ||
The validity of a diagnosis of heart failure in a hospital discharge register | Q36139616 | ||
Good clinical practice and the conduct of clinical studies in pediatric oncology | Q36513759 | ||
Clinical trials bureaucracy: unintended consequences of well-intentioned policy | Q36684575 | ||
Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies | Q37229332 | ||
Improving the quality of care for women with cardiovascular disease: report of a DCRI Think Tank, March 8 to 9, 2007. | Q37343049 | ||
Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects | Q37671448 | ||
National heart, lung, and blood institute (NHLBI) strategic visioning: setting an agenda together for the NHLBI of 2025. | Q38388612 | ||
Cardiovascular drug development: is it dead or just hibernating? | Q38424497 | ||
The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research | Q38464684 | ||
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations | Q38509188 | ||
Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias? | Q38558787 | ||
Trends in characteristics of cardiovascular clinical trials 2001-2012. | Q38571969 | ||
Smart Technology in Lung Disease Clinical Trials | Q38989121 | ||
Who refuses enrollment in cardiac clinical trials? | Q40181022 | ||
Randomized clinical trials: slow death by a thousand unnecessary policies? | Q40190701 | ||
Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants | Q40997434 | ||
PCORnet: turning a dream into reality | Q42717224 | ||
Randomized clinical trials--removing unnecessary obstacles | Q43559306 | ||
Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials | Q43763352 | ||
The randomized registry trial--the next disruptive technology in clinical research? | Q44663056 | ||
Patients treated at multiple acute health care facilities: quantifying information fragmentation | Q44800723 | ||
Thrombus aspiration during ST-segment elevation myocardial infarction | Q44802449 | ||
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial | Q45368659 | ||
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators | Q46066044 | ||
Postmarket evaluation of breakthrough technologies | Q47428805 | ||
Recruitment for controlled clinical trials: literature summary and annotated bibliography | Q49109414 | ||
The Good Clinical Practice guideline: a bronze standard for clinical research. | Q53618862 | ||
The Clinical Trials Transformation Initiative: innovation through collaboration. | Q54198280 | ||
Treatment with Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research | Q56928525 | ||
Ethical and scientific implications of the globalization of clinical research | Q58670198 | ||
The PRECIS-2 tool: designing trials that are fit for purpose | Q59391915 | ||
Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group | Q69883535 | ||
World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects | Q73135842 | ||
Evidence-based medicine in the EMR era | Q82309776 | ||
Re-inventing clinical trials through TransCelerate | Q85893248 | ||
The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm | Q85958281 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 872-880 | |
P577 | publication date | 2016-03-01 | |
P1433 | published in | Circulation | Q578091 |
P1476 | title | Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds | |
P478 | volume | 133 |
Q64096727 | A Data Element-Function Conceptual Model for Data Quality Checks |
Q49996971 | A Novel Patient Recruitment Strategy: Patient Selection Directly from the Community through Linkage to Clinical Data. |
Q38376419 | Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study |
Q59797747 | C-Reactive Protein Levels at the Midpregnancy Can Predict Gestational Complications |
Q33646584 | Cancer Immunoprevention and Public Health |
Q99239521 | Challenges for the evaluation of digital health solutions-A call for innovative evidence generation approaches |
Q64039489 | Conducting real-world evidence studies in India |
Q64993345 | From clinical trials of antiepileptic drugs to treatment. |
Q38372022 | Improving public health by improving clinical trial guidelines and their application |
Q50660284 | Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge. |
Q48123359 | Key interventions and quality indicators for quality improvement of STEMI care: a RAND Delphi survey. |
Q55276312 | Leading causes of cardiovascular hospitalization in 8.45 million US veterans. |
Q98577245 | More than a box to check: Research sponsor and clinical investigator perspectives on making GCP training relevant |
Q91781840 | Placebo Effects in Psychotherapy: A Framework |
Q91729549 | Plasma microRNA: A novel non-invasive biomarker for HBV-associated liver fibrosis staging |
Q37710165 | Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions |
Q59336332 | Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol |
Q38788621 | Standards for Clinical Research: Keeping Pace With the Technology of the Future |
Q64917411 | The Glomerular Disease Study and Trial Consortium: A Grassroots Initiative to Foster Collaboration and Innovation. |
Q59336904 | Validation of a claims-based algorithm identifying eligible study subjects in the ADAPTABLE pragmatic clinical trial |
Search more.